The Latest Cardiac and Vascular News
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
Collaborative research highlights the significance of AI-powered care coordination in acute stroke management FORT MYERS, Fla., July 24, 2024 /PRNewswire/ — TeleSpecialists, LLC, the largest inpatient provider of TeleStroke and TeleNeurology services in the nation, announced the…
Other new investors include Viking Global Investors and RA Capital Management Funding will support Magenta’s clinical programs in support of FDA approval for Elevate, the world’s smallest heart pump KADIMA, Israel, July 23, 2024 /PRNewswire/ — Magenta Medical, developer of Elevate™, the world’s smallest heart pump, has closed a $105M financing round led by global healthcare […]
COLORADO SPRINGS, Colo. & ALISO VIEJO, Calif.–(BUSINESS WIRE)–MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced the recently published results of the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms. The CLEVER study was a […]
YOKNEAM, Israel & COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Rapid Medical™, a leading developer of advanced endovascular devices, announces the first procedures in the USA with the breakthrough deflectable access platform DRIVEWIRE 24 at the 2024 Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting. With active technology, DRIVEWIRE articulates a wide range of catheters for […]
Collaboration aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrial fibrillation procedures Collaboration aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrial fibrillation procedures
Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows expansion of Xeltis’ clinical presence in the US after recent IDE approval for aXess™ US pivotal trial EINDHOVEN, Netherlands, July 23,…
Company Simultaneously Announces Close of $20 Million Financing Round, US FDA 510(k) Clearance of Neurovascular Radical Catheter and Initial Post-Market Clinical Experience Company Simultaneously Announces Close of $20 Million Financing Round, US FDA 510(k) Clearance of Neurovascular Radical Catheter and Initial Post-Market Clinical Experience
ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 second quarter on Monday, August 12, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi” Shamir to its Board of Directors.
